Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost

Current Eye Research

Volumn 33, Issue 5-6, 2008, Pages 477-482

  Costagliola, Ciro ^a   Campa, Claudio ^b   Perri, Paolo ^b   Parmeggiani, Francesco ^b   Romano, Mario R ^a   Incorvaia, Carlo ^b  

^a UNIVERSITY OF MOLISE   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

Intraocular pressure; Ketorolac; Non steroidal anti inflammatory drugs

Indexed keywords

EYE DROPS; KETOROLAC; LATANOPROST; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIHYPERTENSIVE AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FEMALE; GLAUCOMA, OPEN-ANGLE; GONIOSCOPY; HUMANS; INTRAOCULAR PRESSURE; KETOROLAC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TONOMETRY, OCULAR; VISUAL ACUITY;

EID: 47349088375     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802100845     Document Type: Article

References (25)

1. Nichols J, Snyder RW. Topical non-steroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol. 1998;9:40-44.
2. Schalnus R. Topical non-steroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217:89-98.
3. Miller SB. Prostaglandins in health and disease: An overview. Semin Arthritis Rheum. 2006;36:37-49.
4. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem. 2007;282:11613-11617.
5. Bito LZ. A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond: The Proctor lecture. Invest Ophthalmol Vis Sci. 2001;42:1126-1133.
6. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19:501-515.
7. Alm A. Prostaglandin derivates as ocular hypotensive agents. Prog Retin Eye Res. 1998;17:291-312.
8. Resul B, Stjernschantz J, Selen G, Bito L. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol. 1997;41(Suppl 2):S47-52.
9. Schalnus R. Topical nonsteroidal anti-inflammatory therapy in ophthalmology. Ophthalmologica. 2003;217:89-98.
10. Sponsel WE, Paris G, Trigo Y, Pena M, Weber A, Sanford K, McKinnon S. Latanoprost and brimonidine: Therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy. Am J Ophthalmol. 2002;133:11-18.
11. Costagliola C, Parmeggiani F, Antinozzi PP, Caccavale A, Cotticelli L, Sebastiani A. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp Eye Res. 2005;81:610-615.
12. Costagliola C, Parmeggiani F, Caccavale A, Sebastiani A. Nimesulide oral administration increases the intraocular pressure-lowering effect of latanoprost in patients with primary open-angle glaucoma. Am J Ophthalmol. 2006;141:379-381.
13. Chiba T, Kashiwagi K, Chiba N, Tsukahara S. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost in patients with primary open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2006;90:314-317.
14. Kashiwagi K, Tsukahara S. Effect of non-steroidal anti-inflammatory ophthalmic solution on intraocular pressure reduction by latanoprost. Br J Ophthalmol. 2003;87:297-301.
15. Buckley MM, Brogden RN. Ketorolac. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990;39:86-109.
16. Ling TL, Combs DL. Ocular bioavailability and tissue distribution of [14C] ketorolac tromethamine in rabbits. J Pharm Sci. 1987;76:289-294.
17. Abran D, Hardy P, Varma DR, Chemtob S. Mechanisms of the biphasic effects of peroxides on the retinal vasculature of newborn and adult pigs. Exp Eye Res. 1995;61:285-292.
18. Li DY, Varma DR, Chemtob S. Up-regulation of brain PGE2 and PGF2 alpha receptors and receptor-coupled second messengers by cyclooxygenase inhibition in newborn pigs. J Pharmacol Exp Ther. 1995;272:15-19.
19. Hardy P, Bhattacharya M, Abran D, Peri KG, Asselin P, Varma DR, Chemtob S, Bhatthacharya M. Increases in retinovascular prostaglandin receptor functions by cyclooxygenase-1 and -2 inhibition. Invest Ophthalmol Vis Sci. 1998;39:1888-1898.
20. Husain S, Kaddour-Djebbar I, Abdel-Latif AA. Alterations in arachidonic acid release and phospholipase C-beta(1) expression in glaucomatous human ciliary muscle cells. Invest Ophthalmol Vis Sci. 2002;43:1127-1134.
21. Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S. Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jpn J Ophthalmol. 2006;50:153-157.
22. Hedman K, Larsson LI. The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican openangle glaucoma or ocular hypertensive patients. Surv Ophthalmol. 2002;47(Suppl 1):S77-89.
23. Kitnarong N, Zhao Y, Netland PA, Kent AR. Efficacy of latanoprost and timolol maleate in black and white patients. Adv Ther. 2004;21:203-213.
24. Sjöquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47(Suppl 1):S6-12.
25. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998;67:179-191.